NRx Total Assets from 2010 to 2024

NRXPW Stock

USD 0.05 0 3.59%

NRx Pharmaceuticals Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets will likely drop to about 6.9 M in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2017-09-30

Previous Quarter

5.3 M

Current Value

4.5 M

Quarterly Volatility

25.1 M

Covid

Check NRx Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NRx Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.8 K, Interest Expense of 114 K or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NRx financial statements analysis is a perfect complement when working with NRx Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of NRx Pharmaceuticals Correlation against competitors.

For more information on how to buy NRx Stock please use our How to Invest in NRx Pharmaceuticals guide.

Latest NRx Pharmaceuticals' Total Assets Growth Pattern

Below is the plot of the Total Assets of NRx Pharmaceuticals over the last few years. Total assets refers to the total amount of NRx Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in NRx Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. NRx Pharmaceuticals' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NRx Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 7.32 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

NRx Total Assets Regression Statistics

	Arithmetic Mean	49,009,844
	Geometric Mean	35,192,806
	Coefficient Of Variation	56.08
	Mean Deviation	24,831,216
	Median	69,565,819
	Standard Deviation	27,483,424
	Sample Variance	755.3T
	Range	67.9M
	R-Value	(0.84)
	Mean Square Error	234.6T
	R-Squared	0.71
	Significance	0.000078
	Slope	(5,184,084)
	Total Sum of Squares	10574.7T

NRx Total Assets History

	2024	6.9 M
	2023	7.3 M
	2022	25.8 M
	2021	32.7 M
	2020	2.9 M
	2019	32.1 M
	2018	70.8 M

Other Fundumenentals of NRx Pharmaceuticals

Intangibles To Total Assets

NRx Pharmaceuticals Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Common Stock	Net Tangible Assets	Long Term Debt	Net Receivables	Capital Surpluse	Net Invested Capital	Short Long Term Debt	Capital Stock	Net Working Capital	Short Term Debt	Current Deferred Revenue
Total Assets		0.98	0.08	0.83	-0.88	0.97	-0.84	-0.49	0.97	0.58	-0.66	0.7	0.58	-0.62	-0.64	-0.71	-0.58	-0.64	0.58
Total Stockholder Equity	0.98		0.09	0.79	-0.87	0.94	-0.92	-0.46	0.94	0.51	-0.6	0.63	0.51	-0.57	-0.59	-0.64	-0.53	-0.59	0.51
Net Debt	0.08	0.09		0.27	-0.33	0.31	-0.11	-0.82	0.31	-0.33	-0.44	0.4	-0.33	-0.59	0.08	-0.08	-0.69	0.08	-0.33
Retained Earnings	0.83	0.79	0.27		-0.88	0.9	-0.61	-0.74	0.89	0.66	-0.93	0.96	0.66	-0.91	-0.85	-0.93	-0.86	-0.85	0.66
Accounts Payable	-0.88	-0.87	-0.33	-0.88		-0.91	0.76	0.64	-0.9	-0.47	0.83	-0.8	-0.47	0.75	0.66	0.8	0.73	0.66	-0.47
Short Term Investments	0.97	0.94	0.31	0.9	-0.91		-0.79	-0.7	1.0	0.5	-0.78	0.81	0.5	-0.79	-0.66	-0.75	-0.76	-0.66	0.5
Total Liab	-0.84	-0.92	-0.11	-0.61	0.76	-0.79		0.35	-0.79	-0.27	0.4	-0.41	-0.27	0.38	0.4	0.41	0.36	0.4	-0.27
Total Current Assets	-0.49	-0.46	-0.82	-0.74	0.64	-0.7	0.35		-0.7	-0.15	0.82	-0.83	-0.15	0.94	0.45	0.57	0.97	0.45	-0.15
Common Stock	0.97	0.94	0.31	0.89	-0.9	1.0	-0.79	-0.7		0.49	-0.78	0.81	0.49	-0.78	-0.65	-0.74	-0.75	-0.65	0.49
Net Tangible Assets	0.58	0.51	-0.33	0.66	-0.47	0.5	-0.27	-0.15	0.49		-0.45	0.61	1.0	-0.42	-0.59	-0.7	-0.33	-0.59	1.0
Long Term Debt	-0.66	-0.6	-0.44	-0.93	0.83	-0.78	0.4	0.82	-0.78	-0.45		-0.96	-0.45	0.95	0.83	0.92	0.93	0.83	-0.45
Net Receivables	0.7	0.63	0.4	0.96	-0.8	0.81	-0.41	-0.83	0.81	0.61	-0.96		0.61	-0.97	-0.81	-0.92	-0.94	-0.81	0.61
Capital Surpluse	0.58	0.51	-0.33	0.66	-0.47	0.5	-0.27	-0.15	0.49	1.0	-0.45	0.61		-0.42	-0.59	-0.7	-0.33	-0.59	1.0
Net Invested Capital	-0.62	-0.57	-0.59	-0.91	0.75	-0.79	0.38	0.94	-0.78	-0.42	0.95	-0.97	-0.42		0.71	0.81	0.99	0.71	-0.42
Short Long Term Debt	-0.64	-0.59	0.08	-0.85	0.66	-0.66	0.4	0.45	-0.65	-0.59	0.83	-0.81	-0.59	0.71		0.93	0.63	1.0	-0.59
Capital Stock	-0.71	-0.64	-0.08	-0.93	0.8	-0.75	0.41	0.57	-0.74	-0.7	0.92	-0.92	-0.7	0.81	0.93		0.75	0.93	-0.7
Net Working Capital	-0.58	-0.53	-0.69	-0.86	0.73	-0.76	0.36	0.97	-0.75	-0.33	0.93	-0.94	-0.33	0.99	0.63	0.75		0.63	-0.33
Short Term Debt	-0.64	-0.59	0.08	-0.85	0.66	-0.66	0.4	0.45	-0.65	-0.59	0.83	-0.81	-0.59	0.71	1.0	0.93	0.63		-0.59
Current Deferred Revenue	0.58	0.51	-0.33	0.66	-0.47	0.5	-0.27	-0.15	0.49	1.0	-0.45	0.61	1.0	-0.42	-0.59	-0.7	-0.33	-0.59

Click cells to compare fundamentals

About NRx Pharmaceuticals Financial Statements

NRx Pharmaceuticals investors use historical fundamental indicators, such as NRx Pharmaceuticals' Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NRx Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Total Assets	7.3 M	6.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for NRx Stock Analysis

When running NRx Pharmaceuticals' price analysis, check to measure NRx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRx Pharmaceuticals is operating at the current time. Most of NRx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRx Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC